Steven Leonard Chapman Sells 9,563 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 9,563 shares of the firm's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the completion of the sale, the chief executive officer now owns 212,541 shares of the company's stock, valued at $29,417,799.81. This trade represents a 4.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The stock was sold at an average price of $146.03, for a total transaction of $978,693.06.
• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41.

Natera Trading Down 3.5 %

NASDAQ:NTRA traded down $4.84 during mid-day trading on Friday, reaching $133.87. The company's stock had a trading volume of 3,247,142 shares, compared to its average volume of 1,377,854. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company's fifty day simple moving average is $156.81 and its two-hundred day simple moving average is $151.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market cap of $18.10 billion, a P/E ratio of -76.06 and a beta of 1.80.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in NTRA. Vanguard Group Inc. increased its stake in Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after buying an additional 2,036,396 shares during the period. Wellington Management Group LLP grew its stake in Natera by 15.7% during the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after buying an additional 439,778 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Natera by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after acquiring an additional 142,201 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the topic of several research analyst reports. Robert W. Baird upped their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Barclays began coverage on Natera in a report on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 target price on the stock. Piper Sandler lifted their price target on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. Finally, Sanford C. Bernstein lifted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and a consensus price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.